These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35514050)

  • 61. Prediction of the exposure to a 400-mg daily dose of efavirenz in pregnancy: is this dose adequate in extensive metabolisers of CYP2B6?
    Chetty M; Danckwerts MP; Julsing A
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1143-1150. PubMed ID: 32377759
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.
    Gandhi M; Greenblatt RM; Bacchetti P; Jin C; Huang Y; Anastos K; Cohen M; Dehovitz JA; Sharp GB; Gange SJ; Liu C; Hanson SC; Aouizerat B;
    J Infect Dis; 2012 Nov; 206(9):1453-61. PubMed ID: 22927450
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS).
    van Rensburg R; Nightingale S; Brey N; Albertyn CH; Kellermann TA; Taljaard JJ; Esterhuizen TM; Sinxadi PZ; Decloedt EH
    Clin Infect Dis; 2022 Aug; 75(3):399-405. PubMed ID: 34882770
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.
    Arab-Alameddine M; Di Iulio J; Buclin T; Rotger M; Lubomirov R; Cavassini M; Fayet A; Décosterd LA; Eap CB; Biollaz J; Telenti A; Csajka C;
    Clin Pharmacol Ther; 2009 May; 85(5):485-94. PubMed ID: 19225447
    [TBL] [Abstract][Full Text] [Related]  

  • 65. High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe.
    Nyakutira C; Röshammar D; Chigutsa E; Chonzi P; Ashton M; Nhachi C; Masimirembwa C
    Eur J Clin Pharmacol; 2008 Apr; 64(4):357-65. PubMed ID: 18057928
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection.
    Vo TT; Varghese Gupta S
    Pharmacotherapy; 2016 Dec; 36(12):1245-1254. PubMed ID: 27779789
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.
    Yimer G; Ueda N; Habtewold A; Amogne W; Suda A; Riedel KD; Burhenne J; Aderaye G; Lindquist L; Makonnen E; Aklillu E
    PLoS One; 2011; 6(12):e27810. PubMed ID: 22162992
    [TBL] [Abstract][Full Text] [Related]  

  • 68. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.
    Ramachandran G; Hemanth Kumar AK; Rajasekaran S; Kumar P; Ramesh K; Anitha S; Narendran G; Menon P; Gomathi C; Swaminathan S
    Antimicrob Agents Chemother; 2009 Mar; 53(3):863-8. PubMed ID: 19124658
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Gene-gene interactions between DRD3, MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of efavirenz in HIV infected patients.
    Sánchez-Martín A; Cabrera Figueroa S; Cruz R; Porras-Hurtado L; Calvo-Boyero F; Rasool M; ; Domínguez-Gil Hurlé A; Carracedo A
    Drug Metab Pharmacokinet; 2016 Oct; 31(5):349-355. PubMed ID: 27665700
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacogenomics and pharmacokinetics of efavirenz 400 or 600 mg in 184 treatment-naive HIV-infected patients in China.
    Chen R; Chen J; Xun J; Hu Z; Huang Q; Zhang R; Steinhart C; Shen Y; Liu L; Lu H
    Pharmacogenomics; 2020 Aug; 21(13):945-956. PubMed ID: 32838647
    [No Abstract]   [Full Text] [Related]  

  • 71. Effect of mid-dose efavirenz concentrations and CYP2B6 genotype on viral suppression in patients on first-line antiretroviral therapy.
    Orrell C; Bienczak A; Cohen K; Bangsberg D; Wood R; Maartens G; Denti P
    Int J Antimicrob Agents; 2016 Jun; 47(6):466-72. PubMed ID: 27211824
    [TBL] [Abstract][Full Text] [Related]  

  • 72. CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women.
    Röhrich CR; Drögemöller BI; Ikediobi O; van der Merwe L; Grobbelaar N; Wright GE; McGregor N; Warnich L
    AIDS Res Hum Retroviruses; 2016 Jun; 32(6):529-38. PubMed ID: 26655325
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review.
    Atwine D; Bonnet M; Taburet AM
    Br J Clin Pharmacol; 2018 Aug; 84(8):1641-1658. PubMed ID: 29624706
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of Efavirenz Mid-dose Plasma Concentration on Long-Term Weight Change Among Virologically Suppressed People Living With HIV.
    Huang SH; Huang WC; Lin SW; Chuang YC; Sun HY; Chang SY; Kuo PH; Wu PY; Liu WC; Chiang C; Hung CC; Chang SC
    J Acquir Immune Defic Syndr; 2021 Jun; 87(2):834-841. PubMed ID: 33587507
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz.
    Mahungu TW; Nair D; Smith CJ; Egan D; Youle M; Johnson MA; Khoo SH; Back DJ; Owen A
    Clin Pharmacol Ther; 2009 Aug; 86(2):204-11. PubMed ID: 19474786
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.
    Manosuthi W; Sukasem C; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Antimicrob Agents Chemother; 2014; 58(4):2268-73. PubMed ID: 24492364
    [TBL] [Abstract][Full Text] [Related]  

  • 77. In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.
    Aouri M; Barcelo C; Ternon B; Cavassini M; Anagnostopoulos A; Yerly S; Hugues H; Vernazza P; Günthard HF; Buclin T; Telenti A; Rotger M; Decosterd LA;
    Drug Metab Dispos; 2016 Jan; 44(1):151-61. PubMed ID: 26553012
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
    Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R;
    Clin Pharmacol Ther; 2015 Oct; 98(4):406-16. PubMed ID: 26044067
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti.
    Haas DW; Severe P; Jean Juste MA; Pape JW; Fitzgerald DW
    J Antimicrob Chemother; 2014 Aug; 69(8):2187-90. PubMed ID: 24695352
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.
    Wyen C; Hendra H; Siccardi M; Platten M; Jaeger H; Harrer T; Esser S; Bogner JR; Brockmeyer NH; Bieniek B; Rockstroh J; Hoffmann C; Stoehr A; Michalik C; Dlugay V; Jetter A; Knechten H; Klinker H; Skaletz-Rorowski A; Fätkenheuer G; Egan D; Back DJ; Owen A;
    J Antimicrob Chemother; 2011 Sep; 66(9):2092-8. PubMed ID: 21715435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.